Company news

Natera, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

October 3, 2023

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

October 2, 2023

Natera Submits First PMA Module to the FDA for Signatera™

October 1, 2023

Natera Announces Senior Leadership Appointments

September 17, 2023

Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

September 13, 2023

Natera Announces Pricing of $250 Million Follow-On Offering

September 6, 2023

Natera Launches Proposed Follow-On Offering

September 5, 2023

Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

August 15, 2023

Natera Reports Second Quarter 2023 Financial Results

August 2, 2023

Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Natera Files Patent Infringement Suit Against NeoGenomics

July 30, 2023

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

July 27, 2023

Natera to Report its Second Quarter 2023 Results on August 3rd

July 26, 2023

Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages

July 16, 2023

Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection

June 3, 2023

New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types

May 29, 2023

Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits

May 14, 2023

Natera Reports First Quarter 2023 Financial Results

May 8, 2023

Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

May 7, 2023

Natera Announces First Quarter 2023 Earnings Conference Call

May 1, 2023

Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting

April 13, 2023

New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma

March 21, 2023

Natera Announces Commercial Payor Coverage for Signatera™

March 1, 2023

Natera Reports Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

February 22, 2023

Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call

February 20, 2023

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer

February 15, 2023

New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease

February 1, 2023

New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023

January 18, 2023

Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer

January 16, 2023

Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients

December 20, 2022

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

December 8, 2022

Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium

December 6, 2022

Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT

December 5, 2022

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

November 20, 2022

Natera Announces Pricing of Follow-On Offering

November 14, 2022

Natera Reports Third Quarter 2022 Financial Results

November 7, 2022

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs

November 1, 2022

Natera to Report its Third Quarter 2022 Results on November 8th

October 31, 2022

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference

October 31, 2022

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer

October 5, 2022

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

October 3, 2022

Natera Announces 2025 ESG Goals with Publication of 2021 Report

September 28, 2022

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

September 11, 2022

Natera Earns Great Place to Work Certification™ for Second Consecutive Year

August 24, 2022

Natera Announces Enrollment Completion for RenaCARE Study

August 10, 2022

Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT

August 9, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.